Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
dc.contributor.author | Ozaslan, Ersin | |
dc.contributor.author | Topaloglu, Ulas Serkan | |
dc.contributor.author | Inanc, Mevlude | |
dc.contributor.author | Erdem, Umut Gokmen | |
dc.contributor.author | Demir, Hacer | |
dc.contributor.author | Arpaci, Erkan | |
dc.contributor.author | Seker, Mehmet Metin | |
dc.contributor.author | Karaaga, Mustafa | |
dc.contributor.author | Kiziltepe, Melih | |
dc.contributor.author | Eker, Baki | |
dc.contributor.author | Ozkan, Metin | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:40:50Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:40:50Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/6730 | |
dc.description | WOS: 000412789500007 | en_US |
dc.description | PubMed ID: 29155512 | en_US |
dc.description.abstract | Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were also given irinotecan and/or oxaliplatin combined with fluoropyrimidine +/- bevacizumab. Tumor response and survival were evaluated using RECIST and Kaplan-Meier method respectively. Results: Sixty patients were included this study. Cetuximab plus FOLFOX was administered to 40 (66.7%) patients as second-line and to 20 (33.3%) as third-line therapy. Themajority of the patients had a good ECOG performance status (PS) (0 or 1). Clinical benefit was partial plus stable disease and it was 75.0% for both of these two lines. The median progression free survival (PFS) was 7.1 months (95% CI=3.2-10.9) and 6.0 months (95% CI=2.4-9.6), in the second- and third-line (p=0.484). The median overall survival (OS) was 14.3 and 9.2 months in second- and third-line therapy respectively (p=0.071). The common toxicities were haematologic and gastrointestinal, mostly grade 1 and 2. Conclusion: The addition of cetuximab to FOLFOX was well-tolerated and had antitumor activity both in second and third-line therapy in patients with mCRC. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | IMPRIMATUR PUBLICATIONS | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | cetuximab | en_US |
dc.subject | chemotherapy | en_US |
dc.subject | colorectal cancer | en_US |
dc.subject | second line | en_US |
dc.subject | third line | en_US |
dc.title | Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer | en_US |
dc.type | article | en_US |
dc.relation.journal | JOURNAL OF BUON | en_US |
dc.contributor.department | [Ozaslan, Ersin -- Inanc, Mevlude] Kayseri Training & Res Hosp, Dept Med Oncol, Kayseri, Turkey -- [Ozaslan, Ersin -- Inanc, Mevlude -- Ozkan, Metin] Erciyes Univ, Dept Med Oncol, Fac Med, Kayseri, Turkey -- [Topaloglu, Ulas Serkan -- Kiziltepe, Melih -- Eker, Baki] Kayseri Training & Res Hosp, Dept Internal Med, TR-38010 Kayseri, Turkey -- [Topaloglu, Ulas Serkan -- Kiziltepe, Melih] Erciyes Univ, Dept Internal Med, Fac Med, Kayseri, Turkey -- [Erdem, Umut Gokmen] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Demir, Hacer] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey -- [Arpaci, Erkan] Bulent Ecevit Univ, Fac Med, Dept Med Oncol, Zonguldak, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Karaaga, Mustafa] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkey | en_US |
dc.identifier.volume | 22 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.endpage | 868 | en_US |
dc.identifier.startpage | 863 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Makale Koleksiyonu [5200]
Article Collection -
Makale Koleksiyonu [5745]
Article Collection -
Öksüz Yayınlar Koleksiyonu - WoS [6162]